What is claimed is:

1 2 3

6

7

8

9

11

12

13

15 16

17

18

19

20 21

22

- 1. An isolated nucleic acid molecule selected from the group consisting of:
- 4 a) a nucleic acid molecule comprising a nucleotide sequence of SEQ ID NO:1, 5 or SEO ID NO:3:
 - a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEO ID NO:2;
 - c) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 285 contiguous amino acids of SEO ID NO: 2; and
 - d) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, 3, or a complement thereof, under stringent conditions.
 - The isolated nucleic acid molecule of claim 1, which is selected from the group consisting of:
 - a) a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 1, SEQ ID
 NO:3; and
 - a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEO ID NO:2.

3. The nucleic acid molecule of claim 1 further comprising vector nucleic acid
 sequences.

25 sequence

4. The nucleic acid molecule of claim 1 further comprising nucleic acid sequences encoding a heterologous polypeptide.

28

A host cell which contains the nucleic acid molecule of claim 1.

29 30 31

6. The host cell of claim 5 which is a mammalian host cell.

32

24

25

2.6

27

28

29

30 31

32

33

7. A non-human mammalian host cell containing the nucleic acid molecule of 1 2 claim 1. 3 8. An isolated polypeptide selected from the group consisting of: 4 5 a) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence of SEO ID NO: 1, SEO ID NO:3, or a complement thereof. 6 a naturally occurring allelic variant of a polypeptide comprising the amino 7 b) acid sequence of SEQ ID NO:2, wherein the polypeptide is encoded by a nucleic acid 8 molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO: 1, SEQ ID 9 NO:3, or a complement thereof under stringent conditions; and 10 a fragment of a polypeptide comprising the amino acid sequence of SEQ ID 11 NO:2, wherein the fragment comprises at least 285 contiguous amino acids of SEQ ID 12 NO:2. 13 14 9. The isolated polypeptide of claim 8 comprising the amino acid sequence of 15 16 SEO ID NO:2. 17 10. The polypeptide of claim 8 further comprising heterologous amino acid 18 sequences. 19 20 An antibody which selectively binds to a polypeptide of claim 8. 21 11. 22 23

- 12.. A method for producing a polypeptide selected from the group consisting of:
- a polypeptide comprising the amino acid sequence of SEQ ID NO:2; a)
- b) a polypeptide comprising a fragment of the amino acid sequence of SEQ ID
- NO:2, wherein the fragment comprises at least 285 contiguous amino acids of SEQ ID NO:2; and
 - a naturally occurring allelic variant of a polypeptide comprising the amino c) acid sequence of SEQ ID NO:2, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, SEQ ID NO:3, or a complement thereof under stringent conditions;
- comprising culturing the host cell of claim 5 under conditions in which the nucleic acid molecule is expressed.

1 2

3

4 5

6

7

8

9

10

11

12 13

15

16

17

18

19 20

21

23

24

25

26

27

28

29

30

32

- 13. A method for detecting the presence of a polypeptide of claim 8 in a sample, comprising:
 - a) contacting the sample with a compound which selectively binds to a polypeptide of claim 8; and
 - b) determining whether the compound binds to the polypeptide in the sample.
 - The method of claim 13, wherein the compound which binds to the polypeptide is an antibody.
 - A kit comprising a compound which selectively binds to a polypeptide of claim 8 and instructions for use.
 - 16. A method for detecting the presence of a nucleic acid molecule of claim 1 in a sample, comprising the steps of:
 - a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and
 - determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample.
 - The method of claim 16, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.
 - 18. A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of claim 1 and instructions for use.
 - A method for identifying a compound which binds to a polypeptide of claim
 comprising the steps of:
 - a) contacting a polypeptide, or a cell expressing a polypeptide of claim 8 with a test compound; and
 - determining whether the polypeptide binds to the test compound.

24

25

The method of claim 19, wherein the binding of the test compound to the 1 20. polypeptide is detected by a method selected from the group consisting of: 2 detection of binding by direct detecting of test compound/polypeptide a) 3 4 binding; detection of binding using a competition binding assay; b) 5 detection of binding using an assay for 33945-mediated signal transduction. c) 7 A method for modulating the activity of a polypeptide of claim 8 comprising 21. 8 contacting a polypeptide or a cell expressing a polypeptide of claim 8 with a compound 9 which binds to the polypeptide in a sufficient concentration to modulate the activity of the 10 polypeptide. 11 12 A method for identifying a compound which modulates the activity of a 13 22. polypeptide of claim 8, comprising: 14 contacting a polypeptide of claim 8 with a test compound; and 15 a) determining the effect of the test compound on the activity of the polypeptide 16 b) to thereby identify a compound which modulates the activity of the polypeptide. 17 18 A composition for treating atherosclerosis or endothelial cell disorders in a 19 23. subject, comprising a compound which modulates the expression or activity of a 33945 20 21 nucleic acid molecule or polypeptide. 22 A method for treating atherosclerosis or endothelial cell disorders in a 23 24.

subject, comprising administering a compound which modulates the expression or activity

of a 33945 nucleic acid molecule or polypeptide.